The DOI matches its Crossref record; 289 of the 289 references it cites were found in a registry or an index.
Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments
Open accessAbstract
Molecular alterations in cancer genes and associated signaling pathways are used to inform new treatments for precision medicine in cancer. Small molecule inhibitors and monoclonal antibodies directed at relevant cancer-related proteins have been instrumental in delivering successful treatments of some blood malignancies (e.g., imatinib with chronic myelogenous leukemia (CML)) and solid tumors (e.g., tamoxifen with ER positive breast cancer and trastuzumab for HER2-positive breast cancer). However, inherent limitations such as drug toxicity, as well as acquisition of de novo or acquired mechanisms of resistance, still cause treatment failure. Here we provide an up-to-date review of the successes and limitations of current targeted therapies for cancer treatment and highlight how recent technological advances have provided a new level of understanding of the molecular complexity underpinning resistance to cancer therapies. We also raise three basic questions concerning cancer drug discovery based on molecular markers and alterations of selected signaling pathways, and further discuss how combination therapies may become the preferable approach over monotherapy for cancer treatments. Finally, we consider novel therapeutic developments that may complement drug delivery and significantly improve clinical response and outcomes of cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–289 of 289
Karakashev, S. V., Fukumoto, T., Zhao, B., Lin, J., Wu, S., Fatkhutdinov, N., Park, P. H., Semenova, G., Jean, S., Cadungog, M. G., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.015 · Cited by 154
Triggers for genomic rearrangements: insights into genomic, cellular and environmental influences
Mani, R. S., & Chinnaiyan, A. M. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2883 · Cited by 153
SGK3 Mediates INPP4B-Dependent PI3K Signaling in Breast Cancer
Gasser, J. A., Inuzuka, H., Lau, A. W., Wei, W., Beroukhim, R., & Toker, A. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.09.023 · Cited by 149
Miller, B. W., Przepiorka, D., de Claro, R. A., Lee, K., Nie, L., Simpson, N. E., Gudi, R., Saber, H., Shord, S. S., Bullock, J. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2522 · Cited by 147
Formisano, L., Stauffer, K. M., Young, C. D., Bhola, N. E., Zotano, Á. G., Jansen, V. M., Estrada, M. M., Hutchinson, K. E., Giltnane, J. M., Schwarz, L. J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1232 · Cited by 145
James, D. I., Smith, K. M., Jordan, A. M., Fairweather, E. E., Griffiths, L. A., Hamilton, N. S., Hitchin, J. R., Hutton, C. P., Jones, S. D., Kelly, P. J., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00609 · Cited by 143
The recognition and removal of cellular poly( ADP ‐ribose) signals
Barkauskaite, E., Jankevicius, G., Ladurner, A. G., Ahel, I., & Timinszky, G. (2013) · FEBS Journal · doi:10.1111/febs.12358 · Cited by 140
Targeting the Raf kinases in human cancer: the Raf dimer dilemma
Durrant, D., & Morrison, D. K. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.399 · Cited by 139
MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer
de Leeuw, R., McNair, C. M., Schiewer, M. J., Neupane, N. P., Brand, L. J., Augello, M. A., Li, Z., Cheng, L. C., Yoshida, A., Courtney, S. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0410 · Cited by 139
Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer
Le, X., Antony, R., Razavi, P., Treacy, D. J., Luo, F., Ghandi, M., Castel, P., Scaltriti, M., Baselga, J. M., & Garraway, L. A. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0305 · Cited by 137
Selective degradation of CDK6 by a palbociclib based PROTAC
Rana, S., Bendjennat, M., Kour, S., King, H. M., Kizhake, S., Zahid, M., & Natarajan, A. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.03.035 · Cited by 135
Xu, X., Angelis, C. D., Burke, K. A., Nardone, A., Hu, H., Qin, L., Veeraraghavan, J., Sethunath, V., Heiser, L. M., Wang, N., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2191 · Cited by 135
Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer
Kettner, N. M., Vijayaraghavan, S., Durak, M. G., Bui, T. N., Kohansal, M., Ha, M. J., Liu, B., Rao, X., Wang, J., Yi, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3274 · Cited by 135
Discovery of an AKT Degrader with Prolonged Inhibition of Downstream Signaling
You, I., Erickson, E. C., Donovan, K. A., Eleuteri, N. A., Fischer, E. S., Gray, N. S., & Toker, A. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.11.014 · Cited by 134
The History and Mechanism of Action of Fulvestrant
Carlson, R. W. (2005) · Clinical Breast Cancer · doi:10.3816/cbc.2005.s.008 · Cited by 133
Tolcher, A. W., Bendell, J. C., Papadopoulos, K. P., Burris, H. A., Patnaik, A., Jones, S. F., Rasco, D. W., Cox, D. S., Durante, M., Bellew, K. M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu482 · Cited by 133
Antitumor Activity of the Selective Pan-RAF Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma
Nakamura, A., Arita, T., Tsuchiya, S., Donelan, J., Chouitar, J., Carideo, E. G., Galvin, K. M., Okaniwa, M., Ishikawa, T., & Yoshida, S. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1825 · Cited by 126
Lee, M. S., Helms, T. L., Feng, N., Gay, J., Chang, Q. E., Tian, F., Wu, J. Y., Toniatti, C., Heffernan, T. P., Powis, G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9153 · Cited by 123
Neurobiology of Cancer: The Role of β-Adrenergic Receptor Signaling in Various Tumor Environments
Mravec, B., Horváthová, Ľ., & Hunáková, Ľ. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217958 · Cited by 123
Vuylsteke, P., Huizing, M. T., Petráková, K., Roylance, R. R., Laing, R. W., Chan, S. Y. T., Abell, F., Gendreau, S. B., Rooney, I. A., Apt, D., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw320 · Cited by 120
Smyth, L. M., Tamura, K., Oliveira, M., Ciruelos, E., Mayer, I. A., Sablin, M., Biganzoli, L., Ambrose, H. J., Ashton, J., Barnicle, A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3953 · Cited by 120
Smyth, L. M., Piha-Paul, S. A., Won, H. H., Schram, A. M., Saura, C., Loi, S., Lu, J. M., Shapiro, G. I., Juric, D., Mayer, I. A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0966 · Cited by 118
Alike but Different: RAF Paralogs and Their Signaling Outputs
Desideri, E., Cavallo, A. L., & Baccarini, M. (2015) · Cell · doi:10.1016/j.cell.2015.04.045 · Cited by 117
ATM-Deficient Cancers Provide New Opportunities for Precision Oncology
Jette, N., Kumar, M., Radhamani, S., Arthur, G., Goutam, S., Yip, S., Kolinsky, M. P., Williams, G. J., Bose, P., & Lees‐Miller, S. P. (2020) · Cancers · doi:10.3390/cancers12030687 · Cited by 116
Rad54 Drives ATP Hydrolysis-Dependent DNA Sequence Alignment during Homologous Recombination
Crickard, J. B., Moevus, C. J., Kwon, Y., Sung, P., & Greene, E. C. (2020) · Cell · doi:10.1016/j.cell.2020.04.056 · Cited by 116
Geuijen, C. A. W., Nardis, C. D., Maussang, D., Rovers, E., Gallenne, T., Hendriks, L. J. A., Visser, T., Nijhuis, R., Logtenberg, T., de Kruif, J., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.003 · Cited by 115
Hijazi, M., Smith, R., Rajeeve, V., Bessant, C., & Cutillas, P. R. (2020) · Nature Biotechnology · doi:10.1038/s41587-019-0391-9 · Cited by 111
Design and synthesis of selective degraders of EGFRL858R/T790M mutant
Zhang, X., Xu, F., Tong, L., Zhang, T., Xie, H., Lu, X., Ren, X., & Ding, K. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112199 · Cited by 110
Phthalimide conjugations for the degradation of oncogenic PI3K
Li, W., Gao, C., Zhao, L., Yuan, Z., Chen, Y., & Jiang, Y. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.03.066 · Cited by 109
Testosterone Surge: Rationale for Gonadotropin-Releasing Hormone Blockers?
Poppel, H. V., & Nilsson, S. F. (2008) · Urology · doi:10.1016/j.urology.2007.12.070 · Cited by 107
Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives
Fang, Y., Liao, G., & Yu, B. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.01.003 · Cited by 106
Nardis, C. D., Hendriks, L. J. A., Poirier, E., Arvinte, T., Gros, P., Bakker, A. B. H., & de Kruif, J. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.793497 · Cited by 105
Intestinal microbiota: a new force in cancer immunotherapy
Dai, Z., Zhang, J., Wu, Q., Fang, H., Shi, C., Li, Z., Lin, C., Tang, D., & Wang, D. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00599-6 · Cited by 104
Wright, N. A., & Goss, G. D. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.06.01 · Cited by 103
Mayer, I. A., Prat, A., Egle, D., Blau, S. H., Fidalgo, J. A. P., Gnant, M., Fasching, P. A., Colleoni, M. A., Wolff, A. C., Winer, E. P., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3160 · Cited by 100
Yu, J., Yan, J., Guo, Q., Chi, Z., Tang, B., Zheng, B., Yu, J., Yin, T., Cheng, Z., Wu, X., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0475 · Cited by 100
Singh, H., Walker, A. J., Amiri-Kordestani, L., Cheng, J., Tang, S., Balcazar, P., Barnett-Ringgold, K., Palmby, T. R., Cao, X., Zheng, N., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3628 · Cited by 99
Phosphoproteomics of Primary Cells Reveals Druggable Kinase Signatures in Ovarian Cancer
Francavilla, C., Lupia, M., Tsafou, K., Villa, A., Kowalczyk, K. M., Jersie-Christensen, R., Bertalot, G., Confalonieri, S., Brunak, S., Jensen, L. J., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.03.015 · Cited by 99
Pancholi, S., Ribas, R., Simigdala, N., Schuster, E. F., Nikitorowicz-Buniak, J., Ressa, A., Gao, Q., Leal, M. F., Bhamra, A., Thornhill, A. M., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1284-6 · Cited by 94
Lheureux, S., Bruce, J. P., Burnier, J. V., Karakasis, K., Shaw, P. A., Clarke, B. A., Yang, S. Y. C., Quevedo, R., Li, T., Dowar, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3677 · Cited by 92
Shapiro, G. I., LoRusso, P., Kwak, E., Pandya, S., Rudin, C. M., Kurkjian, C., Cleary, J. M., Pilat, M. J., Jones, S., de Crespigny, A., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-019-00776-6 · Cited by 90
Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer
Donnella, H. J., Webber, J. T., Levin, R. S., Camarda, R., Momcilovic, O., Bayani, N., Shah, K. N., Korkola, J. E., Shokat, K. M., Goga, A., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0081-9 · Cited by 90
Hamilton, E. P., Patel, M. R., Armstrong, A. C., Baird, R. D., Jhaveri, K. L., Hoch, M., Klinowska, T. C. M., Lindemann, J. P. O., Morgan, S. R., Schiavon, G., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3102 · Cited by 89
Coles, G. L., Cristea, S., Webber, J. T., Levin, R. S., Moss, S. M., He, A., Sangodkar, J., Hwang, Y. C., Arand, J., Drainas, A. P., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.05.003 · Cited by 88
CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma
Zhou, J. R., Wu, Z., Wong, G. S., Pectasides, E., Nagaraja, A. K., Stachler, M. D., Zhang, H., Chen, T., Zhang, H., Liu, J. B., et al. (2017) · Nature Communications · doi:10.1038/ncomms13897 · Cited by 80
Origanti, S., Cai, S.-R., Munir, A. Z., White, L. S., & Piwnica-Worms, H. (2013) · Oncogene · doi:10.1038/onc.2012.84 · Cited by 74
Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma
Olmez, I., Zhang, Y., Manigat, L. C., Benamar, M., Brenneman, B. R., Nakano, I., Godlewski, J. A., Bronisz, A., Lee, J., Abbas, T., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3124 · Cited by 68
Mutational signatures reveal the role of RAD52 in p53-independent p21-driven genomic instability
Galanos, P., Pappas, G., Polyzos, A., Kotsinas, A., Svolaki, I., Giakoumakis, N. N., Glytsou, C., Pateras, I. S., Swain, U., Souliotis, V. L., et al. (2018) · Genome Biology · doi:10.1186/s13059-018-1401-9 · Cited by 67
Allele-specific tumor spectrum in Pten knockin mice
Wang, H., Karikomi, M., Naidu, S. K., Rajmohan, R., Caserta, E., Chen, H., Rawahneh, M., Moffitt, J., Stephens, J. A., Fernández, S., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912524107 · Cited by 66
Foidart, P., Yip, C., Radermacher, J., Blacher, S., Liénard, M., Montero‐Ruiz, L., Maquoi, E., Montaudon, É., Château‐Joubert, S., Collignon, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1880 · Cited by 58
Rogers, R. F., Walton, M. I., Cherry, D. L., Collins, I., Clarke, P. A., Garrett, M. D., & Workman, P. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-1372 · Cited by 58
Gatti-Mays, M. E., Karzai, F. H., Soltani, S. N., Zimmer, A. S., Green, J. E., Lee, M.-J., Trepel, J. B., Yuno, A., Lipkowitz, S., Nair, J. R., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0491 · Cited by 58
Moureau, S., Luessing, J., Harte, E. C., Voisin, M., & Lowndes, N. F. (2016) · Open Biology · doi:10.1098/rsob.160225 · Cited by 53
Wada, M., Horinaka, M., Yamazaki, T., Katoh, N., & Sakai, T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113217 · Cited by 50 · cited 1×
“Next-generation MEK inhibitors are also available, such as RO5126766, which is defined as a dual Raf/MEK inhibitor that complexes with both proteins and inhibits phosphorylation of ERK in NRAS melanoma cells and in KRAS mutant xenograft models [174,175].”
BackgroundRedundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors.
Luo, M., & Fu, L.-W. (2014) · Europe PMC (PubMed Central) · Cited by 50
Gornstein, E. L., Sandefur, S., Chung, J., Gay, L. M., Holmes, O., Erlich, R., Soman, S., Martin, L.-A., Rose, A. V., Stephens, P. J., et al. (2017) · Clinical Breast Cancer · doi:10.1016/j.clbc.2017.12.010 · Cited by 49
Prognostic Significance of p21 and p53 Expression in Gastric Cancer
Seo, Y., Joo, Y., Choi, S.-K., Rew, J., Park, C.-S., & Kim, S.-J. (2003) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2003.18.2.98 · Cited by 48
Siebert, R., Willers, C. P., & Opalka, B. (1996) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199609054859 · Cited by 48
The PTEN Tumor Suppressor Forms Homodimers in Solution
Heinrich, F., Chakravarthy, S., Nanda, H., Papa, A., Pandolfi, P. P., Ross, A. H., Harishchandra, R. K., Gericke, A., & Lösche, M. (2015) · Structure · doi:10.1016/j.str.2015.07.012 · Cited by 47
Self-citationGenome-Wide Interrogation of Human Cancers Identifies EGLN1 Dependency in Clear Cell Ovarian Cancers
Price, C. O., Gill, S., Ho, Z. V., Davidson, S. M., Merkel, E., McFarland, J. M., Leung, L., Tang, A., Kost‐Alimova, M., Tsherniak, A., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2674 · Cited by 47
Lee, B. Y., Hochgräfe, F., Lin, H., Castillo, L. E., Wu, J., Raftery, M. J., Shreeve, S. M., Horvath, L. G., & Daly, R. J. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0225-t · Cited by 46
Monitoring protein communities and their responses to therapeutics
Budayeva, H. G., & Kirkpatrick, D. S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0063-y · Cited by 45
PI3K Inhibitors and Their Role as Novel Agents for Targeted Therapy in Lymphoma
Sapon-Cousineau, V., Sapon-Cousineau, S., & Assouline, S. E. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00746-8 · Cited by 45
Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs
Green, J. L., Okerberg, E. S., Sejd, J. R., Palafox, M., Monserrat, L., Alemayehu, S., Wu, J., Sykes, M., Aban, A., Serra, V., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0755 · Cited by 43
Ramurthy, S., Taft, B. R., Aversa, R. J., Barsanti, P. A., Burger, M. T., Lou, Y. C., Nishiguchi, G., Rico, A. C., Setti, L., Smith, A., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00161 · Cited by 43
Lhota, F., Zemánková, P., Kleiblová, P., Soukupová, J., Vočka, M., Stránecký, V., Janatová, M., Hartmannová, H., Hodaňová, K., Kmoch, S., et al. (2016) · Clinical Genetics · doi:10.1111/cge.12748 · Cited by 40
Mingbin, Z., LI, J., Wang, L., Tian, Z., ZHANG, P., Xu, Q., Zhang, C., Wei, F., & Chen, W. (2013) · Oncology Letters · doi:10.3892/ol.2013.1381 · Cited by 39
Xie, D., Lan, L., Huang, K., Chen, L., Xu, C., Wang, R., Shi, Y., Wu, X., Wang, L., Liu, Y., et al. (2014) · Oncology Reports · doi:10.3892/or.2014.3538 · Cited by 37
High-Throughput Assessment of Kinome-Wide Activation States
Schmidlin, T., Debets, D. O., van Gelder, C. A. G. H., Stecker, K. E., Rontogianni, S., van den Eshof, B. L., Kemper, K., Lips, E. H., van den Biggelaar, M., Peeper, D. S., et al. (2018) · Cell Systems · doi:10.1016/j.cels.2019.08.005 · Cited by 37
Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial
Goel, S., Pernas, S., Tan‐Wasielewski, Z., Barry, W. T., Bardia, A., Rees, R., Andrews, C., Tahara, R. K., Trippa, L., Mayer, E. L., et al. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.05.010 · Cited by 35
Noeparast, A., Giron, P., Brakeleer, S. D., Eggermont, C., Ridder, U. D., Teugels, E., & Grève, J. D. (2018) · Oncotarget · doi:10.18632/oncotarget.24576 · Cited by 34
Park, P. H., Yamamoto, T. M., Li, H., Alcivar, A. L., Xia, B., Wang, Y., Bernhardy, A. J., Turner, K. M., Kossenkov, A. V., Watson, Z. L., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0256 · Cited by 33
Kinase inhibition profiles as a tool to identify kinases for specific phosphorylation sites
Watson, N. A., Cartwright, T. N., Lawless, C., Cámara-Donoso, M., Sen, O., Sako, K., Hirota, T., Kimurâ, H., & Higgins, J. M. G. (2020) · Nature Communications · doi:10.1038/s41467-020-15428-0 · Cited by 33
Hosford, S. R., Dillon, L. M., Bouley, S. J., Rosati, R., Yang, W., Chen, V. S., Demidenko, E., Morra, R. P., & Miller, T. W. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2764 · Cited by 30
Abramson, V. G., Supko, J. G., Ballinger, T. J., Cleary, J. M., Hilton, J. F., Tolaney, S. M., Chau, N. G., Cho, D. C., Pearlberg, J., Lager, J. J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1764 · Cited by 29
HDAC inhibitor PAC-320 induces G2/M cell cycle arrest and apoptosis in human prostate cancer
Dong, Z., Yang, Y., Liu, S., Lü, J., Huang, B., & Zhang, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.23070 · Cited by 29
Hong, R., Edgar, K. A., Song, K., Steven, S., Young, A. E., Hamilton, P., Arrazate, A., de la Cruz, C., Chan, C., Pang, J., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.sabcs17-pd4-14 · Cited by 27
Exploring the Synergy between PARP and CHK1 Inhibition in Matched BRCA2 Mutant and Corrected Cells
Smith, H. L., Prendergast, L., & Curtin, N. J. (2020) · Cancers · doi:10.3390/cancers12040878 · Cited by 25
Yip, H. Y. K., Chee, A., Ang, C., Shin, S., Ooms, L. M., Mohammadi, Z., Phillips, W. A., Daly, R. J., Cole, T. J., Bronson, R. T., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.09.027 · Cited by 23
Self-citationA venetoclax bench-to-bedside story
Dinardo, C. D., & Konopleva, M. Y. (2021) · Nature Cancer · doi:10.1038/s43018-020-00165-6 · Cited by 22
Gibson, B. A., & Kraus, W. L. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-6993-7_9 · Cited by 20
Yu, L., Fu, F., Li, J., Huang, M., Zeng, B., Lin, Y., Mei, Q., Lv, J., & Wang, C. (2020) · Journal of Oncology · doi:10.1155/2020/5169278 · Cited by 19
Schultink, A. H. M. D. V., Bol, K., Doornbos, R. P., Murat, A., Wasserman, E., Dorlo, T. P. C., Schellens, J. H. M., Beijnen, J. H., & Huitema, A. D. R. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00858-2 · Cited by 18
Opposite Prognostic Impact of Single PTEN-loss andPIK3CAMutations in Early High-risk Breast Cancer
Lazaridis, G. T., Kotoula, V., Vrettou, E., Kostopoulos, I. S., Manousou, K., Papadopoulou, K., Giannoulatou, E., Bobos, M., Sotiropoulou, M. G., Pentheroudakis, G. E., et al. (2019) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20125 · Cited by 17
Ohashi, S., Kikuchi, O., Nakai, Y., Ida, T., Saito, T., Kondo, Y., Yamamoto, Y., Mitani, Y., Vu, T. H. N., Fukuyama, K., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0918 · Cited by 16
Edgar, K. A., Hanan, E. J., Staben, S. T., Schmidt, S., Hong, R., Song, K. W., Young, A. E., Hamilton, P., Arrazate, A., de la Cruz, C., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-156 · Cited by 15
Janyst, K., Janyst, M., Kłopotowska, M., & Lasek, W. (2018) · Oncology Reports · doi:10.3892/or.2018.6248 · Cited by 13
Papa, A., Cordon‐Cardo, C., Bernardi, R., & Pandolfi, P. P. (2012) · Genes & Cancer · doi:10.1177/1947601912473604 · Cited by 5
Self-citationSong, K. W., Edgar, K. A., Kirkpatrick, D. S., Phu, L., Schmidt, S., Nannini, M., Hong, R., Cheng, E., Crocker, L., Young, A. E., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-146 · Cited by 3
Cited by
PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?
Peng, Y., Wang, Y., Zhou, C., Mei, W., & Zeng, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.819128 · Cited by 763
The Curious Case of the HepG2 Cell Line: 40 Years of Expertise
Arzumanian, V. A., Kiseleva, O. I., & Poverennaya, E. V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313135 · Cited by 387
Pathological implication of protein post-translational modifications in cancer
Pan, S., & Chen, R. (2022) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2022.101097 · Cited by 263
Metadata
- Authors
- Yip, H. Y. K., & Papa, A.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2021-03-16
- Volume
- 10
- Issue
- 3
- Pages
- 659
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W3139023757
- Cited by
- 316
- References
- 289
- FWCI
- 25.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.